GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Calipharms KGET · USD

Industrials · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Calipharms

Its shares trade under the ticker KGET. It has been listed since 13 July 2001.

Kleangas Energy Technologies, Inc. engages in the medical marijuana-cannabis business. The company is headquartered in Tampa, Florida. The company went IPO on 2001-07-13. The firm is engaged in designing, manufacturing and selling oxy-hydrogen systems. These systems function by creating oxygen and hydrogen from distilled water through electrolysis and injecting these gases into the mixture of fuel and air used in gasoline and diesel internal combustion engines. In August 2013, the Company acquired a Patent Pending Oxy-Hydrogen Generator Technology for all types of gas and diesel internal combustion engines. Effective June 27, 2014, the Company announced that it has completed the acquisition of Green Day Technologies, Inc.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Industrials
Industry
Machinery
Listed since
13 Jul 2001
Employees
5

Leadership

Pay as last reported

  • Mr. Bo LintonPresident, Chief Executive Officer, Director, since 2014
  • William WylieActing Chief Financial Officer, Director, since 2012$60,000
  • Bryan GeerDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Calipharms Inc has a strong reputation in the pharmaceutical industry.
  • The company has a diverse portfolio of high-quality products.
  • They have established strategic partnerships with leading healthcare providers.
  • Calipharms Inc has a highly skilled and experienced management team.

Weaknesses

  • The company relies heavily on a few key suppliers, which poses a supply chain risk.
  • Calipharms Inc has limited presence in international markets.
  • They have struggled to adapt to rapidly changing regulatory environments.
  • The company lacks significant digital presence and e-commerce capabilities.

Opportunities

  • The global pharmaceutical market is projected to grow significantly in the coming years, providing opportunities for expansion.
  • Calipharms Inc can leverage their expertise to develop innovative products and capture market share.
  • Emerging markets offer untapped potential for growth and diversification.
  • The increasing demand for personalized medicine opens up new avenues for Calipharms Inc.

Threats

  • Intense competition in the pharmaceutical industry puts pressure on pricing and profitability.
  • Stringent regulations and compliance requirements pose risks for Calipharms Inc.
  • The threat of counterfeit drugs impacts brand reputation and patient safety.
  • Shifts in healthcare policies and government regulations can impact market dynamics.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.